celgene

What celgene does

Celgene previously operated as an independent biopharmaceutical company focused on cancer and immunology medicines and was acquired by Bristol Myers Squibb (BMS) in 2019; the entity is now a legacy brand operating under the BMS corporate umbrella. Bristol Myers Squibb is a publicly traded global biopharmaceutical company (NYSE: BMY) headquartered in Summit, New Jersey, with international subsidiaries including Bristol-Myers Squibb, S.A.U. in Madrid, Spain, and dedicated R&D infrastructure including the CITRE hematology center in Seville. The company's core activity is the development, manufacture, and commercialization of prescription pharmaceutical products across five therapeutic areas: oncology, hematology, immunology, cardiovascular disease, and virology.

Its technology base spans small molecules, monoclonal antibodies, immunomodulatory agents, kinase inhibitors, immune checkpoint inhibitors, and proprietary cellular therapies, including two commercialized CAR-T products (Abecma for relapsed/refractory multiple myeloma and Breyanzi for hematological malignancies) and checkpoint inhibitors targeting PD-1 (Opdivo), CTLA-4 (Yervoy), and the LAG-3 / PD-1 combination Opdualag. The active portfolio also includes the oral anticoagulant Eliquis, the multiple-myeloma franchise Revlimid / Imnovid / Empliciti, the cardiac myosin inhibitor Camzyos for obstructive hypertrophic cardiomyopathy, the TYK2 inhibitor Sotyktu for plaque psoriasis, the S1P modulator Zeposia for multiple sclerosis and ulcerative colitis, and additional oncology, virology, and transplant products. Core R&D capabilities include cellular therapies, personalized medicines, and a Seville-based hematology research center focused on identifying new therapeutic targets.

BMS generates revenue through direct prescription pharmaceutical product sales, with distribution via enterprise field sales to hospitals, treatment centers, licensed pharmacies, and pharmaceutical wholesalers across 40+ countries in the Americas, Asia-Pacific, Europe, and the Middle East. Pricing is not publicly disclosed and is determined by country-specific regulatory frameworks; products are dispensed only through authorized healthcare providers. The go-to-market motion combines country-specific commercial operations and websites, healthcare-provider engagement programs, patient support and disease-awareness campaigns, and digital channels (LinkedIn, X, YouTube) targeting healthcare professionals, patients and caregivers, and researchers. A 2019 acquisition of Celgene added the hematology and immunology franchises that now sit at the core of the company's oncology and immunology portfolio.

Name

celgene

Legal name

Bristol-Myers Squibb, S.A.U.

Website

https://celgene.es

Company type

Public

Operating status

Operating

Short description

Bristol Myers Squibb is a global biopharmaceutical company (NYSE: BMY), previously known as Celgene, that develops and commercializes prescription medicines in oncology, hematology, immunology, cardiovascular, and virology, including CAR-T therapies and immune checkpoint inhibitors, selling through enterprise field sales to healthcare providers across more than 40 countries.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Oncology Specialty Pharmaceuticals (HLAIACAA)

akta.pro secondary industries

Specialty Care Pharmaceuticals (HLAIAAAB), Oncology & Hematology Pharmaceuticals (HLAIAAAC), Immunology & Inflammation Pharmaceuticals (HLAIAAAD)

Keywords

• Biopharmaceutical medicines
• Oncology therapeutics
• Immunology treatments
• Cellular therapies
• Hematology drugs

Headquarters

HQ city

Summit

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical product sales: BMS develops, manufactures, and commercializes biopharmaceutical medicines across multiple therapeutic areas including oncology, immunology, cardiovascular, and hematology. The company generates revenue through direct sales of prescription pharmaceutical products.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Celgene (now part of Bristol Myers Squibb) develops, manufactures, and commercializes prescription biopharmaceutical medicines for cancer, immune disorders, cardiovascular conditions, and hematological diseases. Its portfolio includes CAR-T cellular therapies, immune checkpoint inhibitors, immunomodulatory drugs for multiple myeloma, anticoagulants, kinase inhibitors, and specialty therapies for psoriasis and multiple sclerosis. Products are sold through enterprise field sales to healthcare providers and distributed via regulated pharmacy and hospital channels.

Product overview

Bristol Myers Squibb is a global biopharmaceutical company offering a diversified portfolio of approved medications across multiple therapeutic areas including oncology, hematology, immunology, cardiovascular diseases, and virology. The product portfolio includes innovative therapies such as CAR-T cell therapies (ABECMA, BREYANZI), immune checkpoint inhibitors (OPDIVO, YERVOY, OPDUALAG), anticoagulants (ELIQUIS), and treatments for multiple myeloma (REVLIMID, IMNOVID, EMPLICITI). The company operates as a unified biopharmaceutical business rather than a platform-based technology product company.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• CITRE research center in Seville is a pioneer in hematology research and identifying new therapeutic targets

Named customers2 records

Segments3 records

Ideal customer profiles3 records

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• TucuviminorStrategic or Co-development PartnerBristol Myers Squibb and Tucuvi collaboration focused on advancing the treatment of cardiomyopathies through technological innovation. The partnership aims to improve cardiomyopathy patient care through technology-driven solutions.

Scale indicators1 record

Recent moves5 records

Expansion highlights5 records

Direct peers

• Merck & Co. Direct peer in oncology: Merck's Keytruda (pembrolizumab) is the leading PD-1 inhibitor competing head-to-head with BMS's Opdivo across multiple tumor types. Both are large-cap diversified biopharmas with oncology, vaccines, and specialty care franchises.
• Pfizer: Direct peer across oncology, immunology, and vaccines. Pfizer competes with BMS in hematology, solid tumors, and inflammatory disease, and through Seagen has built a competing oncology biologics portfolio.
• Roche: Direct peer in oncology and immunology. Roche markets competing immune checkpoint inhibitors (Tecentriq), a deep hematology franchise (including Polivy, Columvi, Lunsumio), and competes with BMS CAR-T via internal cell therapy efforts.
• Novartis: Direct peer across oncology, hematology, and immunology. Novartis was the first to commercialize an FDA-approved CAR-T therapy (Kymriah) and competes directly with BMS in hematology and cardiovascular (Entresto vs. Eliquis/Camzyos).
• AstraZeneca: Direct peer in oncology and specialty care: AstraZeneca markets the competing PD-L1 inhibitor Imfinzi, has built a major hematology franchise post-Alexion, and increasingly overlaps with BMS in immunology and rare disease.
• Johnson & Johnson: Direct peer in oncology, hematology, and immunology: J&J's Darzalex/Carvykti franchise (the latter co-developed with Legend Biotech) directly competes with BMS's multiple myeloma assets including Revlimid and Abecma.
• Eli Lilly: Direct peer in oncology, immunology, and cardiometabolic disease. Lilly's Tagrisso, Verzenio, and expanding immunology pipeline (Olumiant, lebrikizumab) overlap with BMS's oncology and specialty care franchises.
• Sanofi: Direct peer in immunology and specialty care: Sanofi's Dupixent franchise and broader immunology pipeline compete with BMS's Sotyktu, Orencia, and Zeposia in autoimmune and inflammatory disease.
• Gilead Sciences (Kite): Direct peer in hematology and CAR-T: Gilead's Kite Pharma subsidiary markets Yescarta and Tecartus, directly competing with BMS's Breyanzi and Abecma in B-cell malignancies and multiple myeloma.
• Amgen: Direct peer in oncology, hematology, and biologics manufacturing. Amgen's oncology biologics (Blincyto, Imdelltra, Tezspire co-developed with AstraZeneca) overlap with BMS hematology and immunology portfolios.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/BMSIberia
• YouTubeyoutube.com/@BMSIberia
• LinkedInlinkedin.com/company/celgene

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about celgene